Possible role of hippocampal GPR55 in spatial learning and memory in rats

Marichal‐Cancino, Bruno A.; Fajardo-Valdez, Alfonso; Ruiz-Contreras, Alejandra E.; Méndez-Dı́az, Mónica; Prospéro-Garcı́a, Oscar

doi:10.21307/ane-2018-001

Cited by 27 publications

(24 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The application of LPI to hippocampal mouse slices enhances the long-term potentiation of CA1 neurons [ 150 ]. Moreover, central administration of LPI and GPR55 agonists promotes procedural memory and provokes changes in spatial memory [ 151 , 152 ]. Central actions of GPR55 seem to rely on its ability to modulate intracellular Ca 2+ presynaptically and boost neurotransmitter release, as observed in the hippocampal CA1 to CA3 subregions of mice brain slices [ 153 ].…”

Section: Inositols In the Brainmentioning

confidence: 99%

The Biomedical Uses of Inositols: A Nutraceutical Approach to Metabolic Dysfunction in Aging and Neurodegenerative Diseases

López-Gambero

Sanjuan²,

Serrano-Castro

et al. 2020

Biomedicines

View full text Add to dashboard Cite

Inositols are sugar-like compounds that are widely distributed in nature and are a part of membrane molecules, participating as second messengers in several cell-signaling processes. Isolation and characterization of inositol phosphoglycans containing myo- or d-chiro-inositol have been milestones for understanding the physiological regulation of insulin signaling. Other functions of inositols have been derived from the existence of multiple stereoisomers, which may confer antioxidant properties. In the brain, fluctuation of inositols in extracellular and intracellular compartments regulates neuronal and glial activity. Myo-inositol imbalance is observed in psychiatric diseases and its use shows efficacy for treatment of depression, anxiety, and compulsive disorders. Epi- and scyllo-inositol isomers are capable of stabilizing non-toxic forms of β-amyloid proteins, which are characteristic of Alzheimer’s disease and cognitive dementia in Down’s syndrome, both associated with brain insulin resistance. However, uncertainties of the intrinsic mechanisms of inositols regarding their biology are still unsolved. This work presents a critical review of inositol actions on insulin signaling, oxidative stress, and endothelial dysfunction, and its potential for either preventing or delaying cognitive impairment in aging and neurodegenerative diseases. The biomedical uses of inositols may represent a paradigm in the industrial approach perspective, which has generated growing interest for two decades, accompanied by clinical trials for Alzheimer’s disease.

show abstract

Section: Inositols In the Brainmentioning

confidence: 99%

The Biomedical Uses of Inositols: A Nutraceutical Approach to Metabolic Dysfunction in Aging and Neurodegenerative Diseases

López-Gambero

Sanjuan²,

Serrano-Castro

et al. 2020

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Administration of LPI onto the hippocampus of rats showed a reduction in the capability of spatial navigation strategy and worsened the capability of finding the escape tunnel in the barnes-maze (BM), a test that performed to assess spatial learning and memory (memory to place objects). In contrast, rats receiving CID16020046, a GPR55 antagonist, spent less time in the target zone during the test, suggesting the involvement of hippocampal CA1 GPR55 in spatial learning and memory (Marichal-Cancino et al, 2018 ). Therefore, all these findings indicate a direct connection of GPR55 to motor function, memory formation, and neuroinflammation, but additional research is merited for its role in microglial activation in neurodegeneration.…”

Section: Microglial Gpcr-mediated Effect On Aβ In Admentioning

confidence: 99%

Importance of GPCR-Mediated Microglial Activation in Alzheimer’s Disease

Haque

Kim

Jakaria

et al. 2018

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder associated with impairment of cognition, memory deficits and behavioral abnormalities. Accumulation of amyloid beta (Aβ) is a characteristic hallmark of AD. Microglia express several GPCRs, which, upon activation by modulators, mediate microglial activation and polarization phenotype. This GPCR-mediated microglial activation has both protective and detrimental effects. Microglial GPCRs are involved in amyloid precursor protein (APP) cleavage and Aβ generation. In addition, microglial GPCRs are featured in the regulation of Aβ degradation and clearance through microglial phagocytosis and chemotaxis. Moreover, in response to Aβ binding on microglial Aβ receptors, they can trigger multiple inflammatory pathways. However, there is still a lack of insight into the mechanistic link between GPCR-mediated microglial activation and its pathological consequences in AD. Currently, the available drugs for the treatment of AD are mostly symptomatic and dominated by acetylcholinesterase inhibitors (AchEI). The selection of a specific microglial GPCR that is highly expressed in the AD brain and capable of modulating AD progression through Aβ generation, degradation and clearance will be a potential source of therapeutic intervention. Here, we have highlighted the expression and distribution of various GPCRs connected to microglial activation in the AD brain and their potential to serve as therapeutic targets of AD.

show abstract

“…Rats bilaterally injected into the dorsolateral striatum with a GPR55 and CB 1 agonist and simultaneously with AM251 showed the most efficient performance in a procedural memory task [66]. To further investigate the GPR55 role in spatial learning, rats that received bilateral infusions of a GPR55 agonist into the hippocampus exhibited serial strategy at the expense of spatial strategy, suggesting that integrity of GPR55 pathway could be required to establish a specific navigational strategy [67]. Accordingly, injections of palmitoylethanolamide into the ventral hippocampus affected spatial memory, probably via GPR55 [68], and hippocampal GPR55 stimulation improved synaptic plasticity [69].…”

Section: Discussionmentioning

confidence: 99%

CB1 Activity Drives the Selection of Navigational Strategies: A Behavioral and c-Fos Immunoreactivity Study

Laricchiuta

Balsamo

Fabrizio

et al. 2020

IJMS

View full text Add to dashboard Cite

To promote efficient explorative behaviors, subjects adaptively select spatial navigational strategies based on landmarks or a cognitive map. The hippocampus works alone or in conjunction with the dorsal striatum, both representing the neuronal underpinnings of the navigational strategies organized on the basis of different systems of spatial coordinate integration. The high expression of cannabinoid type 1 (CB1) receptors in structures related to spatial learning—such as the hippocampus, dorsal striatum and amygdala—renders the endocannabinoid system a critical target to study the balance between landmark- and cognitive map-based navigational strategies. In the present study, mice treated with the CB1-inverse agonist/antagonist AM251 or vehicle were trained on a Circular Hole Board, a task that could be solved through either navigational strategy. At the end of the behavioral testing, c-Fos immunoreactivity was evaluated in specific nuclei of the hippocampus, dorsal striatum and amygdala. AM251 treatment impaired spatial learning and modified the pattern of the performed navigational strategies as well as the c-Fos immunoreactivity in the hippocampus, dorsal striatum and amygdala. The present findings shed light on the involvement of CB1 receptors as part of the selection system of the navigational strategies implemented to efficiently solve the spatial problem.

show abstract

Possible role of hippocampal GPR55 in spatial learning and memory in rats

Cited by 27 publications

References 42 publications

The Biomedical Uses of Inositols: A Nutraceutical Approach to Metabolic Dysfunction in Aging and Neurodegenerative Diseases

The Biomedical Uses of Inositols: A Nutraceutical Approach to Metabolic Dysfunction in Aging and Neurodegenerative Diseases

Importance of GPCR-Mediated Microglial Activation in Alzheimer’s Disease

CB1 Activity Drives the Selection of Navigational Strategies: A Behavioral and c-Fos Immunoreactivity Study

Contact Info

Product

Resources

About